Production (Stage)
BioXcel Therapeutics, Inc.
BTAI
$1.39
$0.021.46%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -40.06M | -59.60M | -71.00M | -107.83M | -153.05M |
| Total Depreciation and Amortization | 307.00K | 309.00K | 310.00K | 312.00K | 316.00K |
| Total Amortization of Deferred Charges | 774.00K | 467.00K | 552.00K | 823.00K | 1.08M |
| Total Other Non-Cash Items | -22.35M | -14.02M | -4.43M | 1.61M | 17.30M |
| Change in Net Operating Assets | -5.03M | 820.00K | -9.51M | -244.00K | 13.99M |
| Cash from Operations | -66.36M | -72.03M | -84.08M | -105.33M | -120.36M |
| Capital Expenditure | -- | -- | 0.00 | 0.00 | -20.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 0.00 | 0.00 | -20.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.50M | -2.50M | -- | -- | -- |
| Issuance of Common Stock | 26.95M | 39.69M | 35.06M | 34.59M | 29.37M |
| Repurchase of Common Stock | -55.00K | -54.00K | -8.00K | -8.00K | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.16M | -474.00K | -547.00K | -533.00K | -369.00K |
| Cash from Financing | 23.24M | 36.66M | 34.51M | 34.05M | 29.00M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -43.13M | -35.37M | -49.57M | -71.27M | -91.38M |